GNI  Group Ltd. Logo

GNI Group Ltd.

Multinational biopharma firm developing drugs, TCMs, and medical devices.

2160 | T

Overview

Corporate Details

ISIN(s):
JP3386370005
LEI:
Country:
Japan
Address:
中央区日本橋本町二丁目2番2号

Description

GNI Group Ltd. is a vertically integrated, multinational biopharmaceutical company engaged in the full spectrum of drug development, from research and clinical trials to manufacturing, sales, and marketing. The company's portfolio includes pharmaceutical drugs, traditional Chinese medicines, and medical devices. Its research and development efforts are primarily focused on creating therapies for diseases such as cancer and inflammation, with a particular emphasis on conditions prevalent in Asian populations. The group utilizes genetic information and analysis technology to advance its drug discovery programs.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2023-11-14 08:06
確認書
Japanese 10.0 KB
2023-11-14 08:05
四半期報告書-第23期第3四半期(2023/07/01-2023/09/30)
Japanese 308.2 KB
2023-08-28 10:10
臨時報告書
Japanese 31.8 KB
2023-08-14 09:44
確認書
Japanese 10.0 KB
2023-08-14 09:21
四半期報告書-第23期第2四半期(2023/04/01-2023/06/30)
Japanese 276.7 KB
2023-05-15 08:16
確認書
Japanese 10.0 KB
2023-05-15 08:10
四半期報告書-第23期第1四半期(2023/01/01-2023/03/31)
Japanese 249.9 KB
2023-03-31 08:13
確認書
Japanese 8.2 KB
2023-03-31 08:12
内部統制報告書-第22期(2022/01/01-2022/12/31)
Japanese 22.1 KB
2023-03-31 08:11
有価証券報告書-第22期(2022/01/01-2022/12/31)
Japanese 1.2 MB
2022-11-14 08:57
確認書
Japanese 10.1 KB
2022-11-14 08:53
四半期報告書-第22期第3四半期(令和4年7月1日-令和4年9月30日)
Japanese 282.1 KB
2022-08-15 09:07
確認書
Japanese 10.1 KB
2022-08-15 09:06
四半期報告書-第22期第2四半期(令和4年4月1日-令和4年6月30日)
Japanese 281.4 KB
2022-05-16 09:16
四半期報告書-第22期第1四半期(令和4年1月1日-令和4年3月31日)
Japanese 259.6 KB

Automate Your Workflow. Get a real-time feed of all GNI Group Ltd. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for GNI Group Ltd.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for GNI Group Ltd. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

4BASEBIO PLC Logo
Manufactures GMP-grade synthetic DNA for next-generation therapeutics and vaccines.
United Kingdom
4BB
4D Molecular Therapeutics, Inc. Logo
Develops genetic medicines using AAV vectors for ophthalmology and pulmonology diseases.
United States of America
FDMT
4SC AG Logo
Biopharmaceutical company with no products under development or operational business.
Germany
VSC
60 DEGREES PHARMACEUTICALS, INC. Logo
Develops and commercializes medicines for infectious diseases, focusing on tropical illnesses.
United States of America
SXTP
89bio, Inc. Logo
Clinical-stage biopharma developing therapies for liver and cardiometabolic diseases.
United States of America
ETNB
Aardvark Therapeutics, Inc. Logo
Clinical-stage biopharma developing therapeutics for hunger and metabolic diseases.
United States of America
AARD
ABBOTT LABORATORIES Logo
Global healthcare company in medical devices, diagnostics, nutrition & pharmaceuticals.
United States of America
ABT
AbbVie Inc. Logo
A research-based biopharmaceutical company developing and manufacturing medicines.
United States of America
ABBV
AbCellera Biologics Inc. Logo
Discovers and develops antibody-based therapeutics using a proprietary platform.
United States of America
ABCL
Develops antibody-based therapeutics using CAR-T, NEST, and AffiMab platforms.
South Korea
174900

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.